See more : PT Tri Banyan Tirta Tbk (ALTO.JK) Income Statement Analysis – Financial Results
Complete financial analysis of DMS Imaging SA (DMSIM.BR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DMS Imaging SA, a leading company in the Biotechnology industry within the Healthcare sector.
- New Work SE (NWO.DE) Income Statement Analysis – Financial Results
- Paion AG (0NF3.L) Income Statement Analysis – Financial Results
- Adroit Infotech Limited (ADROITINFO.NS) Income Statement Analysis – Financial Results
- Evergreen Lithium Limited (EG1.AX) Income Statement Analysis – Financial Results
- Veolia Environnement S.A. (VEOEF) Income Statement Analysis – Financial Results
DMS Imaging SA (DMSIM.BR)
About DMS Imaging SA
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 5.00K | 7.00K |
| Cost of Revenue | 23.02M | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 3.00K | 0.00 | -3.00K |
| Gross Profit | 12.26M | 0.00 | 0.00 | 0.00 | -1.00K | 0.00 | 0.00 | 1.00K | 5.00K | 10.00K |
| Gross Profit Ratio | 34.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 25.00% | 100.00% | 142.86% |
| Research & Development | 0.00 | 0.00 | -53.00K | 13.91M | 10.86M | 10.90M | 12.12M | 6.69M | 3.54M | 1.67M |
| General & Administrative | 420.00K | 423.00K | 478.00K | 1.57M | 1.38M | 833.00K | 1.27M | 526.00K | 229.00K | 401.00K |
| Selling & Marketing | 227.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 647.00K | 423.00K | 478.00K | 1.57M | 1.38M | 833.00K | 1.27M | 526.00K | 229.00K | 401.00K |
| Other Expenses | 16.78M | -4.30M | 251.49K | 473.23K | 534.00K | 226.97K | -1.11M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.43M | -3.88M | 676.49K | 15.95M | 12.77M | 11.96M | 12.28M | 7.64M | 4.32M | 2.31M |
| Cost & Expenses | 40.44M | -3.88M | 676.49K | 15.95M | 12.77M | 11.96M | 12.28M | 7.64M | 4.32M | 2.31M |
| Interest Income | 3.00K | 0.00 | 74.00K | 0.00 | 0.00 | 6.00K | 38.00K | 31.00K | 6.00K | 13.00K |
| Interest Expense | 234.00K | 7.00K | 503.00K | 208.00K | -507.00K | -2.00K | 92.00K | 102.00K | 112.00K | 31.00K |
| Depreciation & Amortization | 3.91M | 26.77K | 446.18K | 848.00K | 253.00K | 205.00K | 141.00K | 80.00K | 20.00K | 22.00K |
| EBITDA | -1.26M | 3.91M | -450.82K | -15.10M | -13.03M | -11.78M | -12.11M | -7.53M | -4.30M | -2.27M |
| EBITDA Ratio | -3.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -188,325.00% | -85,940.00% | -32,371.43% |
| Operating Income | -5.17M | 3.89M | -897.00K | -15.95M | -12.77M | -11.98M | -12.28M | -7.64M | -4.32M | -2.30M |
| Operating Income Ratio | -14.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -191,000.00% | -86,360.00% | -32,828.57% |
| Total Other Income/Expenses | -414.00K | 11.00K | -465.00K | 295.00K | -1.56M | -9.00K | -60.00K | -75.00K | -111.00K | -21.00K |
| Income Before Tax | -5.58M | 3.90M | -1.36M | -15.66M | -14.32M | -11.99M | -12.34M | -7.72M | -4.43M | -2.32M |
| Income Before Tax Ratio | -15.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -192,875.00% | -88,580.00% | -33,128.57% |
| Income Tax Expense | -6.00K | 1.00K | 735.18K | 208.00K | -3.00K | 2.00K | 1.00K | 27.00K | 1.00K | 10.00K |
| Net Income | -5.58M | 3.90M | -2.10M | -15.86M | -14.32M | -11.99M | -12.34M | -7.72M | -4.43M | -2.32M |
| Net Income Ratio | -15.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -192,875.00% | -88,580.00% | -33,128.57% |
| EPS | 0.00 | 0.16 | -0.10 | -0.78 | -0.86 | -0.94 | -1.10 | -0.91 | -0.52 | -0.27 |
| EPS Diluted | 0.00 | 0.16 | -0.10 | -0.78 | -0.86 | -0.94 | -1.10 | -0.91 | -0.52 | -0.27 |
| Weighted Avg Shares Out | 1.49B | 24.10M | 21.89M | 20.35M | 16.72M | 12.81M | 11.22M | 8.50M | 8.50M | 8.50M |
| Weighted Avg Shares Out (Dil) | 1.49B | 24.10M | 21.89M | 20.35M | 16.72M | 12.81M | 11.22M | 8.50M | 8.50M | 8.50M |
Source: https://incomestatements.info
Category: Stock Reports